Standout Papers

Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular ca... 2022 2026 2023 2024109
  1. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial (2022)
    ZhiCheng Lai, Minke He et al. European Journal of Cancer

Immediate Impact

64 standout
Sub-graph 1 of 23

Citing Papers

The emerging role of lactate in tumor microenvironment and its clinical relevance
2024 Standout
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
2024 Standout
1 intermediate paper

Works of Anna Kan being referenced

Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
2021

Author Peers

Author Last Decade Papers Cites
Anna Kan 333 314 260 37 863
Koji Miyahara 272 269 304 44 887
Yunlong Cui 292 451 283 50 1.0k
Amy K. Kim 210 265 258 26 927
Joerg Trojan 313 214 306 30 914
Wei Wu 269 429 272 46 1.0k
Lin Zhou 248 255 200 28 814
Xiang Xiao 229 343 379 28 1.0k
Yefa Yang 346 219 243 39 797
Yuji Eso 371 146 282 52 779
Maria Grazia Diodoro 164 365 430 41 1.1k

All Works

Loading papers...

Rankless by CCL
2026